Skip to Page Content
Top Groups:
hostvouchet
Shopping
General
International News
US Business
Leisure Lifestyles
Social Networking
Bookmarking
(more »)
Post Details
-
Dynavax Announces Termination Of Partnership With Merck For HEPLISAV™ Hepatitis B Vaccine - All Rights Revert To Dynavax
Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the termination of a global license and development collaboration agreement with Merck & Co., Inc. for HEPLISAVTM, a Phase 3 hepatitis B virus (HBV) vaccine. All rights to develop and c...
- Saved By: healthmaster01
- Tags: partnership , of , merck , for , vaccine , with , b , hepatitis , termination , announces , dynavax , and heplisav™
- Group: (none)
post comments
[Add Comment]
Copyright ©2009 Searchles, Inc. All Rights Reserved
